Nerve Stimulation During Esophagectomy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04171011|
Recruitment Status : Completed
First Posted : November 20, 2019
Last Update Posted : October 29, 2020
Esophagectomy is the cornerstone for treatment of esophageal cancer. However, it is associated with substantial morbidity and mortality. Studies suggest that systemic inflammation after surgery has a negative impact on surgical outcomes. Attenuation of an excessive inflammatory response within the perioperative period for high-risk surgical procedures may reduce morbidity and mortality. The inflammatory response may be important in the development of these complications and reduction of inflammatory cytokine may be associated with an improved outcome.
The current study will evaluate the feasibility and safety of neuromodulation during minimally invasive surgery for esophageal cancer (esophagectomy) to assess impact on the inflammatory response. During the esophagectomy, a stimulation lead will be placed on the exposed nerves, and energy applied to the lead to test whether the nerves can be activated. The study will also measure potential physiological responses to nerve activation.
|Condition or disease||Intervention/treatment||Phase|
|Inflammatory Response||Device: Stimulator device||Not Applicable|
Active dampening of the inflammatory response may be an important therapeutic target to decrease complications and improve recovery following esophagectomy. The current study is intended to evaluate the feasibility and safety of stimulating the exposed nerves in esophagectomy patients.
During minimally invasive esophagectomy, a neurovascular bundle (NVB) is exposed or partially exposed as part of the obligatory lymph node dissection. At the point in the esophagectomy when the NVB is being isolated, a lead will be applied laparoscopically to the NVB and connected to an external pulse generator. An ultrasound transducer will be introduced to the abdomen and placed on the NVB to visualize splenic arterial blood flow. The NVB will be stimulated while physiologic responses are observed. Blood samples will be taken before, and at certain pre-defined time points after, stimulation and recovery. The lead and ultrasound transducer will be removed after completion of stimulation, and the esophagectomy surgery will continue. Surgeon experience applying and removing the cuff electrode will be documented, in addition to the responses to NVB stimulation. Post-operative safety will be followed through 7-days (or day of discharge if earlier).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||14 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Device Feasibility|
|Official Title:||Feasibility of Splenic Nerve Stimulation During Esophagectomy|
|Actual Study Start Date :||November 28, 2019|
|Actual Primary Completion Date :||October 6, 2020|
|Actual Study Completion Date :||October 6, 2020|
Experimental: Nerve Stimulation
Participants will undergo brief NVB stimulation during the esophagectomy procedure.
Device: Stimulator device
The stimulator device will be used to electrically stimulate the NVB
- Feasibility applying and removing the stimulation lead: Proportion of participants in whom the lead was successfully applied and removed [ Time Frame: 1 day ]Proportion of participants in whom the lead was successfully applied and removed
- Safety of placement, stimulation and removal of the lead: Incidence of adverse events [ Time Frame: 7 days ]Incidence of adverse events
- Peak Systolic Velocity (PSV) blood flow change measured by doppler ultrasound [ Time Frame: Before stimulation and during stimulation ]
- End Diastolic Velocity (EDV) blood flow change measured by doppler ultrasound [ Time Frame: Before stimulation and during stimulation ]
- Velocity Time Integral (VTI) blood flow change measured by doppler ultrasound [ Time Frame: Before stimulation and during stimulation ]
- Heart Rate (HR) change [ Time Frame: Before stimulation and during stimulation ]
- Systolic Blood Pressure (SBP) change [ Time Frame: Before stimulation and during stimulation ]
- Diastolic Blood Pressure (DBP) change [ Time Frame: Before stimulation and during stimulation ]
- Mean Arterial Blood Pressure (MAP) change [ Time Frame: Before stimulation and during stimulation ]
- Hematology (white blood cell (WBC) counts) [ Time Frame: Before stimulation to Day 1 post stimulation ]
- Cytokine IL-6 [ Time Frame: Before stimulation to Day 1 post stimulation ]
- Cytokine IL-8 [ Time Frame: Before stimulation to Day 1 post stimulation ]
- Cytokine IL-10 [ Time Frame: Before stimulation to Day 1 post stimulation ]
- Cytokine TNF [ Time Frame: Before stimulation to Day 1 post stimulation ]
- C-Reactive Protein level [ Time Frame: At days 2 and 3 post stimulation ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04171011